Recursion Pharmaceuticals - About the company
Recursion Pharmaceuticals is a public company based in New York (United States), founded in 2013 by Blake Borgeson and Dean Y Li. It operates as an AI-enabled drug discovery and development platform for novel therapeutics. Recursion Pharmaceuticals has raised $452M in funding from investors like Felicis Ventures, DCVC and Advantage Capital. The company has 252 active competitors, including 80 funded and 15 that have exited. Its top competitors include companies like Schrodinger, Relay Therapeutics and Atomwise.
Company Details
AI-enabled drug discovery and development platform for novel therapeutics. It focuses on identifying new targets and designing optimized molecules. The platform utilizes biological and chemical datasets, machine learning models, and a supercomputer to accelerate the discovery of medicines. It aims to improve the speed and efficiency of drug development for conditions with high unmet needs, including cancers and rare diseases. The company also forms strategic partnerships to expand its impact on patients.
- Website
- recursion.com
- Email ID
- *****@recursion.com
- Phone Number
- +1 **********
- Registered Address
- Salt Lake City, Utah
Key Metrics
Founded Year
2013
Location
New York, United States
Stage
Public
Total Funding
$452M in 19 rounds
Latest Funding Round
Investors
Ranked
2nd among 252 active competitors
Annual Revenue
$50M - $100M as on Dec 31, 2025
Employee Count
2 as on Sep 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public
Legal entities associated with Recursion Pharmaceuticals
Recursion Pharmaceuticals is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Recursion Pharmaceuticals, LLC CIN: 1601830 , United States, Active | $1 - $1M (As on Dec 04, 2015) | - | - | |
Recursion Pharmaceuticals, Inc. CIN: 6727635 , United States, Active | Feb 08, 2023 | - | - | - |
RECURSION PHARMACEUTICALS, INC. CIN: 1601830 , United States, Active | Apr 01, 2014 | $50M - $100M (As on Dec 31, 2025) | 400 (As on Dec 31, 2021) | - |
RECURSION PHARMACEUTICALS LLC CIN: 464099738 , United States, Active | Dec 31, 1999 | - | 453 (As on Dec 31, 2024) | - |
Recursion Pharmaceuticals's IPO details
Recursion Pharmaceuticals got listed on Apr 16, 2021.
Click here to take a look at Recursion Pharmaceuticals's IPO in detail
Sign up to download Recursion Pharmaceuticals' company profile
Recursion Pharmaceuticals's funding and investors
Recursion Pharmaceuticals has raised a total funding of $452M over 19 rounds. Its first funding round was on Jan 01, 2014. Its latest funding round was a Post IPO round on Jul 12, 2023 for $*****. 1 investor participated in its latest round. Recursion Pharmaceuticals has 49 institutional investors.
Here is the list of recent funding rounds of Recursion Pharmaceuticals:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 12, 2023 | 3865985 | Post IPO | 7772133 | 3306328 | 8858977 | 6800947 |
Oct 25, 2022 | 4355260 | Post IPO | 7563694 | 6539207 | 9465574 | |
Sep 09, 2020 | 4639756 | Series D | 8890982 | 9252286 |
View details of Recursion Pharmaceuticals's funding rounds and investors
Recursion Pharmaceuticals' founders and board of directors
Founder? Claim ProfileThe founders of Recursion Pharmaceuticals are Blake Borgeson and Dean Y Li.
Here are the details of Recursion Pharmaceuticals' key team members:
- Blake Borgeson: Co-Founder, Board Member of Recursion Pharmaceuticals. They are also an angel investor in 1 startup.
- Dean Y Li: Co-Founder & Board Member of Recursion Pharmaceuticals.
View details of Recursion Pharmaceuticals's Founder profiles and Board Members
Recursion Pharmaceuticals' employee count trend
Recursion Pharmaceuticals has 2 employees as of Sep 26. Here is Recursion Pharmaceuticals's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Recursion Pharmaceuticals's Competitors and alternates
Top competitors of Recursion Pharmaceuticals include Schrodinger, Relay Therapeutics and Atomwise. Here is the list of Top 10 competitors of Recursion Pharmaceuticals, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Schrodinger 1990, New York City (United States), Acquired | Provider of a web-based simulation and modelling tool | $162M | 74/100 | |
2nd | Recursion Pharmaceuticals 2013, New York (United States), Public | AI-enabled drug discovery and development platform for novel therapeutics | $452M | 64/100 | |
3rd | Relay Therapeutics 2016, Cambridge (United States), Public | Developer of drug discovery platform and study protein motion | $520M | 70/100 | |
4th | Atomwise 2012, San Francisco (United States), Series B | Developer of artificial intelligence platform for small molecule drug discovery | $219M | 67/100 | |
5th | Valo Health 2019, Boston (United States), Series B | AI-powered platform for drug discovery and development | $450M | 67/100 | |
6th | XtalPi 2014, Cambridge (United States), Public | AI-based drug research and development company | $785M | 67/100 | |
7th | Isomorphic Labs 2021, London (United Kingdom), Series B | Digital platform focused on revolutionizing drug discovery using AI | $2.7B | 64/100 | |
8th | Xaira 2023, San Francisco (United States), Series D | AI-enabled platform for drug discovery and development | $1B | 63/100 | |
9th | In Silico 2014, Boston (United States), Public | AI-enabled bioinformatics platform for drug discovery and biomarker development | $510M | 62/100 | |
10th | Tandem AI 2021, New York (United States), Series A | AI-based drug discovery tool for researchers | $82M | 62/100 |
Looking for more details on Recursion Pharmaceuticals's competitors? Click here to see the top ones
Recursion Pharmaceuticals's Investments and acquisitions
Recursion Pharmaceuticals has not made any investments yet. Recursion Pharmaceuticals has made 4 acquisitions.Here is the list of latest three $acquisitions:
Filter this list
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Aug 08, 2024 | Acquisition | 2012 | Oxford (United Kingdom) | |
May 08, 2023 | Acquisition | 2013 | Toronto (Canada) | |
May 08, 2023 | Acquisition | 2017 | Montreal (Canada) |
See all acquisitions by Recursion Pharmaceuticals
Reports related to Recursion Pharmaceuticals
Here is the latest report on Recursion Pharmaceuticals's sector:
News related to Recursion Pharmaceuticals
Media has covered Recursion Pharmaceuticals for a total of 24 events in the last 1 year, 9 of them have been about company updates and 4 about people movement.
•
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common StockFinancial Post•Oct 15, 2026•Recursion Pharmaceuticals
•
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their CollaborationFinancial Post•Oct 15, 2026•Recursion Pharmaceuticals, Sanofi
•
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation ModelBusiness Wire•Sep 21, 2026•Recursion Pharmaceuticals, Tempus
•
Recursion Pharmaceuticals Director Blake Bogeson Receives $100,200Investing•Sep 03, 2026•Recursion Pharmaceuticals
•
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery ProgramStock Screener•Aug 05, 2026•Recursion Pharmaceuticals, Genentech
•
Recursion Pharmaceuticals Announces Grant of Inducement AwardsGlobeNewswire•Aug 01, 2026•Recursion Pharmaceuticals
•
Recursion Pharmaceuticals Director Sells $158,500 Worth of StockInvesting•Jul 10, 2026•Recursion Pharmaceuticals
•
•
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6GlobeNewswire•Apr 29, 2026•Recursion Pharmaceuticals
•
Altitude Labs Empowers Biotech Founders with Educational Accelerator ProgramBioSpace•Apr 29, 2026•Recursion Pharmaceuticals
Are you a Founder ?
FAQs about Recursion Pharmaceuticals
Explore our recently published companies
- Marketing Agency - Deptford based, 2020 founded, Unfunded company
- Aquiyel Services - Houston based, 2020 founded, Public company
- B2clogin.com - 2017 founded, Unfunded company
- Compose Finance - Warsaw based, 2024 founded, Unfunded company
- Bubbls - United Kingdom based, Unfunded company
- TedhiMedhi Family - India based, Unfunded company